

**DAFTAR PUSTAKA**

1. Nepogodiev D, Martin J, Biccard B, Makupe A, Bhangu A, Ademuyiwa A, et al. Global burden of postoperative death. *The Lancet*. 2019;393(10170):401.
2. Lerman BJ, Popat RA, Assimes TL, Heidenreich PA, Wren SM. Association of left ventricular ejection fraction and symptoms with mortality after elective noncardiac surgery among patients with heart failure. *Jama*. 2019;321(6):572–9.
3. Nearman H, Klick JC, Eisenberg P, Pesa N. Perioperative complications of cardiac surgery and postoperative care. *Crit Care Clin*. 2014;30(3):527–55.
4. Azarfarin R, Ashouri N, Totonchi Z, Bakhshandeh H, Yaghoubi A. Factors influencing prolonged ICU stay after open heart surgery. *Res Cardiovasc Med*. 2014;3(4):1–5.
5. Schultz-Swarthfigure CT, McCall P, Docking R, Galley HF, Shelley B. Can soluble urokinase plasminogen receptor predict outcomes after cardiac surgery? *Interact Cardiovasc Thorac Surg*. 2021 Jan 22;32(2):236–43.
6. Hote M. Cardiac surgery risk scoring systems: In quest for the best. *Heart Asia*. 2018;10(1).
7. Polineni S, Parker DM, Alam SS, Thiessen-Philbrook H, McArthur E, DiScipio AW, et al. Predictive Ability of Novel Cardiac Biomarkers ST 2, Galectin-3, and NT-Pro BNP Before Cardiac Surgery. *J Am Heart Assoc*. 2018;7(14):e008371.
8. Brown JR, Jacobs JP, Alam SS, Thiessen-Philbrook H, Everett A, Likosky DS, et al. Utility of biomarkers to improve prediction of readmission or mortality after cardiac surgery. *Ann Thorac Surg*. 2018;106(5):1294–301.
9. Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL. suPAR: a new biomarker for cardiovascular disease? *Can J Cardiol*. 2015;31(10):1293–302.
10. Zeng M, Chang M, Zheng H, Li B, Chen Y, He W, et al. Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis. *Am J Emerg Med*. 2016;34(3):375–80.
11. Mossanen JC, Pracht J, Jansen TU, Buendgens L, Stoppe C, Goetzenich A, et al. Elevated soluble urokinase plasminogen activator receptor and proenkephalin serum levels predict the development of acute kidney injury after cardiac surgery. *Int J Mol Sci*. 2017;18(8):1662.
12. Petersen JEV, Kallelose T, Barton KD, Caspi A, Rasmussen LJH. Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis. *BMJ Open*. 2020 Jul;10(7):e036125.

13. Tuomi H, Kultti J, Danielsson J, Kangastupa P, Åkerman K, Niemelä O. Serum soluble urokinase plasminogen activator receptor in alcoholics: Relation to liver disease severity, fibrogenesis, and alcohol use. *J Gastroenterol Hepatol.* 2014;29(12):1991–5.
14. Eugen-Olsen J, Giamarellos-Bourboulis EJ. suPAR: The unspecific marker for disease presence, severity and prognosis. *Int J Antimicrob Agents.* 2015;46:S33–4.
15. Velissaris D, Pierrakos C, Karamouzos V, Pantzaris ND, Gogos C. The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review. *Acta Clin Belg.* 2021 Jan 2;76(1):79–84.
16. Velissaris D, Zareifopoulos N, Koniari I, Karamouzos V, Bousis D, Gerakaris A, et al. Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease. *J Clin Med Res.* 2021;13(3):133–42.
17. Velissaris D, Dimopoulos G, Parissis J, Alexiou Z, Antonakos N, Babalis D, et al. Prognostic role of soluble urokinase plasminogen activator receptor at the emergency department: a position paper by the Hellenic sepsis study group. *Infect Dis Ther.* 2020;9:407–16.
18. Rasmussen SR, Nielsen RV, Eriksson F, Dons M, Vedel AG, Buggeskov KB, et al. Prognostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity C-Reactive Protein on Postoperative Mortality in Patients Undergoing Elective On-Pump Cardiac Surgery. *J Cardiothorac Vasc Anesth.* 2021 Aug;35(8):2415–23.
19. Gozdzik W, Adamik B, Gozdzik A, Rachwalik M, Kustrzycki W, Kübler A. Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use. *PLoS One.* 2014;9(6):e98923.
20. Lyngbæk S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. *Int J Cardiol.* 2013;167(3):781–5.
21. Mekonnen G, Corban MT, Hung OY, Eshtehardi P, Eapen DJ, Al-Kassem H, et al. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. *Atherosclerosis.* 2015;239(1):55–60.
22. Stoner L, Lucero AA, Palmer BR, Jones LM, Young JM, Faulkner J. Inflammatory biomarkers for predicting cardiovascular disease. *Clin Biochem.* 2013;46(15):1353–71.

23. Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Pretorius R, Schutte AE. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. *Int J Cardiol.* 2015;184:631–6.
24. Theilade S, Lyngbaek S, Hansen T, Eugen-Olsen J, Fenger M, Rossing P, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. *J Intern Med.* 2015;277(3):362–71.
25. Eapen DJ, Manocha P, Ghasemzadeh N, Patel RS, Al Kassem H, Hammadah M, et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. *J Am Heart Assoc.* 2014;3(5):e001118.
26. Nezic D, Spasic T, Micovic S, Kosevic D, Balevic M, Petrovic I, et al. Clinical performances of the EuroSCORE II in a single-centre, contemporary cardiac surgical cohort. *J Cardiothorac Surg.* 2015;10:1–1.
27. Melly L, Torregrossa G, Lee T, Jansens JL, Puskas JD. Fifty years of coronary artery bypass grafting. *J Thorac Dis.* 2018;10(3):1960.
28. Islam MY ul, Ahmed MU, Khan MS, Bawany FI, Khan A, Arshad MH. On pump coronary artery bypass graft surgery versus off pump coronary artery bypass graft surgery: a review. *Glob J Health Sci.* 2014;6(3):186.
29. Hardiman SC, Villan Villan YF, Conway JM, Sheehan KJ, Sobolev B. Factors affecting mortality after coronary bypass surgery: a scoping review. *J Cardiothorac Surg.* 2022;17(1):45.
30. Saxton A, Chaudhry R, Manna B. Anatomy, thorax, heart right coronary arteries. 2019;
31. Diodato M, Chedrawy EG. Coronary artery bypass graft surgery: the past, present, and future of myocardial revascularisation. *Surg Res Pract.* 2014;2014.
32. Rianda R, Semedi B, Subagjo A, Avidar Y. EuroSCORE II as predictor of mortality and morbidity in post-CABG patient in Dr. Soetomo General Academic Hospital. *Indones J Anesth Reanim.* 2022;4(1):14.
33. Bulow NMH, Colpo E, Duarte MF, Correa EFM, Schlosser RS, Lauda A, et al. Inflammatory response in patients under coronary artery bypass grafting surgery and clinical implications: a review of the relevance of dexmedetomidine use. *Int Sch Res Not.* 2014;2014.
34. Pilkington S, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. *Anaesthesia.* 2015;70(1):56–70.

35. Almashrafi A, Alsabti H, Mukaddirov M, Balan B, Aylin P. Factors associated with prolonged length of stay following cardiac surgery in a major referral hospital in Oman: a retrospective observational study. *BMJ Open*. 2016;6(6):e010764.
36. Schoffelen A, Hofhuis J, Rommes J, Spronk P. Consumption of ICU resources by long-stay patients does not change over time: 10-year observation in a teaching hospital in The Netherlands. *Crit Care*. 2008;12(Suppl 2):P525.
37. Williams NS, BULSTRODE CJ, O'CONNELL RP. Bailey & Love's: SHORT PRACTICE OF SURGERY. *II G Chir-J Ital Surg Assoc*. 2010;31(4):197.
38. Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. *Ann Thorac Surg*. 2004;78(2):527–34.
39. Gadeltayeb FAG, Malik EM, Elnur EE. Incidence, Indications, and Risk Factors of Reopening After Cardiac Surgery in Tertiary Cardiac Center, Sudan: Retrospective Observational Study. *J Cardiol Res Rev Rep*. 2020;1(1):1–7.
40. Salazar JD, Wityk RJ, Grega MA, Borowicz LM, Doty JR, Petrofski JA, et al. Stroke after cardiac surgery: short-and long-term outcomes. *Ann Thorac Surg*. 2001;72(4):1195–201.
41. Filsoufi F, Castillo JG, Rahmanian PB, Broumand SR, Silvay G, Carpentier A, et al. Epidemiology of deep sternal wound infection in cardiac surgery. *J Cardiothorac Vasc Anesth*. 2009;23(4):488–94.
42. Graf K, Ott E, Vonberg RP, Kuehn C, Haverich A, Chaberny IF. Economic aspects of deep sternal wound infections. *Eur J Cardiothorac Surg*. 2010;37(4):893–6.
43. van Wingerden JJ, Lapid O, Boonstra PW, de Mol BA. Muscle flaps or omental flap in the management of deep sternal wound infection. *Interact Cardiovasc Thorac Surg*. 2011;13(2):179–88.
44. Gårdlund B. Postoperative surgical site infections in cardiac surgery—an overview of preventive measures. *Apmis*. 2007;115(9):989–95.
45. Gummert J, Barten M, Hans C, Kluge M, Doll N, Walther T, et al. Mediastinitis and cardiac surgery-an updated risk factor analysis in 10,373 consecutive adult patients. *Thorac Cardiovasc Surg*. 2002;50(02):87–91.
46. Seabra VF, Alobaidi S, Balk EM, Poon AH, Jaber BL. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized controlled trials. *Clin J Am Soc Nephrol*. 2010;5(10):1734–44.

47. Boodhwani M, Rubens FD, Wozny D, Nathan HJ. Effects of mild hypothermia and rewarming on renal function after coronary artery bypass grafting. *Ann Thorac Surg.* 2009;87(2):489–95.
48. Rajakaruna C, Rogers C, Angelini G, Ascione R. Risk factors for and economic implications of prolonged ventilation after cardiac surgery. *J Thorac Cardiovasc Surg.* 2005;130(5):1270–7.
49. Loosen SH, Tacke F, Binnebosel M, Leyh C, Vucur M, Heitkamp F, et al. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases. *Oncotarget.* 2018;9(43):27027.
50. Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, et al. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure. *JACC Heart Fail.* 2017 Apr;5(4):268–77.
51. Alstrup M, Meyer J, Schultz M, Rasmussen LJH, Rasmussen LS, Køber L, et al. Soluble urokinase plasminogen activator receptor (suPAR) as an added predictor to existing preoperative risk assessments. *World J Surg.* 2019;43:780–90.
52. Loosen SH, Gorgulho J, Jördens MS, Schulze-Hagen M, Beier F, Vucur M, et al. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy. *Front Oncol.* 2021 Apr 1;11:646883.
53. Hayek SS, Divers J, Raad M, Xu J, Bowden DW, Tracy M, et al. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein. *J Am Heart Assoc.* 2018 May;7(9):e008194.
54. Hodges GW, Bang CN, Eugen-Olsen J, Olsen MH, Boman K, Ray S, et al. SuPAR predicts cardiovascular events and mortality in patients with asymptomatic aortic stenosis. *Can J Cardiol.* 2016;32(12):1462–9.
55. Chalkias A, Mouzarou A, Samara E, Xanthos T, Ischaki E, Pantazopoulos I. Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. *Mol Diagn Ther.* 2020 Oct;24(5):517–21.
56. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. *Crit Care.* 2011;15:1–14.

57. Backes Y, Van Der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. *Intensive Care Med.* 2012 Sep;38(9):1418–28.
58. Okonta KE, Anbarasu M, Agarwal V, Jamesraj J, Kurian VM, Rajan S. Sternal wound infection following open heart surgery: appraisal of incidence, risk factors, changing bacteriologic pattern and treatment outcome. *Indian J Thorac. Cardiovasc. Surg.* 2011;27:28–32.
59. Sommerer C, Zeier M, Morath C, Reiser J, Scharnagl H, Stojakovic T, et al. Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography. *Sci Rep.* 2019 Jan 24;9(1):475.
60. Chenevier-Gobeaux C, Lemarechal H, Doumenc B, Peschanski N, Claessens YE, Borderie D, et al. Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome. *Clin. Biochem.* 2021 Jun;92:19–24.
61. Musa AF, Cheong XP, Dillon J, Nordin RB. coronary artery bypass grafting (CABG) surgery at the National Heart Institute, Kuala Lumpur: a retrospective review.[version 2; peer review: 1 approved, 1 approved with reservations].
62. Borde D, Gandhe U, Hargave N, Pandey K, Khullar V. The application of European system for cardiac operative risk evaluation II (EuroSCORE II) and Society of Thoracic Surgeons (STS) risk-score for risk stratification in Indian patients undergoing cardiac surgery. *Ann. Card. Anaesth.* 2013;16(3):163–6.